HCW Biologics (HCWB) Accounts Payables (2020 - 2025)

HCW Biologics (HCWB) has 6 years of Accounts Payables data on file, last reported at $118000.0 in Q4 2025.

• Quarterly Accounts Payables fell 99.47% year-over-year to $118000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $118000.0 (down 99.47% YoY) and the FY2025 annual result came in at $118000.0, down 99.47% from the prior year.
• Accounts Payables eased to $118000.0 in Q4 2025, from $19.0 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $22.7 million in Q3 2024 to a low of $118000.0 in Q4 2025.
• A 5-year average of $6.3 million and a median of $2.1 million in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2024 — Accounts Payables jumped 885.48% — and 2025, when it slumped 99.47%.
• Tracing HCWB's Accounts Payables over 5 years: stood at $223664.0 in 2021, then surged by 660.07% to $1.7 million in 2022, then soared by 52.94% to $2.6 million in 2023, then surged by 758.93% to $22.3 million in 2024, then tumbled by 99.47% to $118000.0 in 2025.
• The last three Accounts Payables figures came in at $118000.0 (Q4 2025), $19.0 million (Q3 2025), and $19.4 million (Q2 2025), per Business Quant data.